In the subsequent, these subject areas are described in the context of the most crucial techniques in adjuvant therapy of EBC.There were no clinically relevant improvements in comparison to 2011 apart from new info and new tips regarding the treatment method with bisphosphonates and denosumab (see segment ‘Bisphosphonates and RANKL Antibody Denos